Presbyterian Healthcare Services and the University of New Mexico Hospital are participating in a study of the COVID-19 treatment bamlanivimab with pharmaceutical company Eli Lilly and Company. The goal is to determine whether bamlanivimab can significantly reduce hospital admissions for certain high-risk patients.
Both Presbyterian and UNMH are already using bamlanivimab to treat mild-to-moderate COVID-19 in patients who are at high risk of progressing to serious disease. This includes patients over age 65 or those who have certain chronic health conditions. The study will allow Presbyterian and UNMH to receive additional bamlanivimab doses and treat up to 3,000 patients over three months.
Bamlanivimab received an Emergency Use Authorization for high-risk COVID-19 patients from the Food and Drug Administration (FDA) in November 2020. Bamlanivimab has not been approved by the FDA for any use.
“Bamlanivimab is a promising treatment for high risk patients with mild or moderate COVID-19 disease,” said Dr. Norbert Topf, Chief Quality Medical Officer, Presbyterian Healthcare Services. “We are thrilled to participate in a study in order to provide treatment options for our patients at highest risk of serious illness from COVID-19.”
“UNM Health is happy to be able to join with Lilly and Presbyterian to provide access for New Mexicans to this type of research and clinical care” said Dr. Alex Rankin, Associate Chief Medical Officer for UNM Hospital. “We look forward to helping develop more options for the care of patients in the ongoing battle against COVID-19. As always, we encourage our community members to help us by continuing to wear their masks and follow COVID-safe practices.”
For more information see the Lilly announcement here.